IZRL vs. CNCR ETF Comparison

Comparison of ARK Israel Innovative Technology ETF (IZRL) to Loncar Cancer Immunotherapy ETF (CNCR)
IZRL

ARK Israel Innovative Technology ETF

IZRL Description

The ARK Israel Innovative Technology ETF (IZRL) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israeli Innovation Index, which is designed to track the price movements of exchange-listed Israeli companies whose main business operations are causing disruptive innovation in the areas of genomics, health care, biotechnology, industrials, manufacturing, the Internet or information technology. The Index includes equity securities and depositary receipts of exchange listed companies that are incorporated and/or domiciled in Israel (‘‘Israeli Companies’’) and are included in one of the following economic sectors as defined by FactSet Research Systems: (i) health technology, (ii) communications, (iii) technology services, (iv) electronic technology, (v) consumer services, or (vi) producer manufacturing.

Grade (RS Rating)

Last Trade

$21.39

Average Daily Volume

14,824

Number of Holdings *

25

* may have additional holdings in another (foreign) market
CNCR

Loncar Cancer Immunotherapy ETF

CNCR Description ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$13.22

Average Daily Volume

3,744

Number of Holdings *

67

* may have additional holdings in another (foreign) market
Performance
Period IZRL CNCR
30 Days 7.11% -13.14%
60 Days 11.06% -15.74%
90 Days 7.36% -11.75%
12 Months 20.37% 25.96%
0 Overlapping Holdings
Symbol Grade Weight in IZRL Weight in CNCR Overlap
IZRL Overweight 25 Positions Relative to CNCR
Symbol Grade Weight
SMWB A 2.78%
FVRR B 2.72%
SSYS B 2.54%
PLTK B 2.33%
INMD C 2.19%
CYBR A 2.16%
MGIC D 2.13%
WIX A 2.12%
CGNT B 2.1%
FROG C 2.07%
RDWR B 2.07%
ITRN B 2.04%
NICE D 2.02%
WKME A 2.02%
CLBT B 2.0%
RSKD D 1.97%
NNOX C 1.96%
BWAY B 1.9%
TEVA C 1.9%
MNDY C 1.87%
MDWD D 1.8%
AUDC D 1.78%
URGN F 1.78%
CHKP C 1.75%
SPNS F 1.54%
IZRL Underweight 67 Positions Relative to CNCR
Symbol Grade Weight
GLUE C -2.03%
EXEL B -1.9%
RVMD C -1.84%
ACLX C -1.73%
BMY B -1.72%
ELVN D -1.68%
XNCR B -1.66%
MRSN D -1.62%
BPMC B -1.58%
KPTI D -1.57%
REPL D -1.56%
GNLX F -1.56%
MGNX F -1.55%
HCM D -1.54%
SWTX C -1.47%
CRBU D -1.47%
JANX C -1.46%
ERAS C -1.46%
DAWN D -1.44%
IMCR D -1.42%
RXRX F -1.39%
SDGR C -1.39%
ARVN F -1.39%
AURA C -1.38%
LYEL F -1.35%
SNDX F -1.34%
MRUS F -1.33%
KYMR D -1.32%
RPTX F -1.32%
GERN D -1.31%
IOVA F -1.3%
RCUS F -1.29%
NRIX C -1.29%
FHTX C -1.26%
NUVB C -1.26%
BNTX C -1.25%
ZNTL F -1.25%
MRK D -1.24%
BCYC F -1.24%
YMAB F -1.24%
BMEA F -1.22%
PGEN F -1.2%
CGEM F -1.2%
ALLO F -1.18%
NUVL C -1.18%
VOR D -1.17%
GMAB F -1.17%
TYRA F -1.16%
KURA F -1.16%
ACRV F -1.15%
AUTL F -1.13%
STRO F -1.12%
LEGN D -1.1%
IDYA F -1.07%
TSVT F -1.06%
REGN F -1.0%
ITOS F -0.98%
IPHA D -0.98%
SMMT D -0.97%
ACET F -0.97%
IMRX F -0.95%
IMTX F -0.93%
RLAY F -0.91%
IGMS F -0.88%
RAPT F -0.88%
FATE F -0.87%
PRLD F -0.55%
Compare ETFs